Omeros Corporation (OMER)
Last updated: 2026-10-20 13:25:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Omeros Corporation (OMER) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.36, with a market capitalization of $1.17B and a P/E ratio of 9.48. Over the past 52 weeks, its price has ranged from $6.24 to $21.24. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.17B | |
$16.32 | |
$30.23 | |
$0.92 | |
$16.35 | |
1.48K | |
1.76M | |
9.48 | |
$21.24 | |
$6.24 | |
-- | |
-- |
Omeros Corporation (OMER) Pre-Market Stock Price
Omeros Corporation (OMER) is trading at $16.36 in pre-market trading as of 2026-10-20 13:08:00, up 0.06% ($0.01) from the previous close of $16.35
Pre-market trading shows how investors are pricing OMER before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Omeros Corporation (OMER) 7-Day Stock Price Change
Over the past seven days, Omeros Corporation (OMER) moved from $19.83 to $16.36, representing a decline of 17.50% ($3.47).
The stock traded between $15.85 and $20.24 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.43 million shares, up versus the previous seven-day period, indicating higher trading activity.
OMER 52-Week Price Position
Position in Range: 67.5%
OMER is currently trading at $16.36, placing it 67.5% of the way from its 52-week low of $6.24 to its 52-week high of $21.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Omeros Corporation (OMER)?
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros Corporation Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 175 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Omeros Corporation (OMER) Stock on MEXC
Eligible investors can buy real shares of Omeros Corporation (OMER) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Omeros Corporation (OMER) stock price today?
2.Is OMER stock going up or down today?
3.What is OMER pre-market price?
4.What is OMER after-hours price?
5.Is OMER stock trading now?
6.Where does OMER sit relative to its 52-week high and low?
7.What sector is Omeros Corporation in?
8.What is Omeros Corporation's market capitalization and where is it listed?
9.How is OMER valued in terms of P/E ratio and EPS?
10.Does Omeros Corporation pay a dividend?
Explore More US Stocks
Search Stocks
OMER Stock Calculator
Estimate the value between OMER shares and USD.
OMER Shares to USD
1.00 OMER shares = 16.36 USD
Calculations are estimates based on the latest available price and are for reference only.


